Long-term Survival After Heart Transplantation: A Population-based Nested Case-Control Study.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
03 2021
Historique:
received: 11 06 2019
revised: 12 02 2020
accepted: 26 05 2020
pubmed: 3 8 2020
medline: 10 3 2021
entrez: 3 8 2020
Statut: ppublish

Résumé

Heart transplantation is the mainstay of treatment for patients in end-stage heart failure. This study sought to contrast survival after transplantation with that of the general population to quantify standardized mortality rates using a nested case-control study design. Control subjects were noninstitutionalized inhabitants of the United States identified through the National Longitudinal Mortality study. Case subjects were adults who underwent heart transplantation between 1990 and 2007 and identified through the Organ Procurement and Transplantation Network. Propensity-matching (5:1, nearest neighbor, caliper = 0.1) was utilized to identify suitable control subjects based on age, sex, race, and state of permanent residency. The primary study endpoint was 10-year survival. In all, 31,883 heart transplant recipients were matched to 159,415 noninstitutionalized residents of the United States. The 10-year survival of heart transplant recipients was 53%. The population expected mortality rate was 15.9 deaths per 100 person-years with an observed rate of 45.1 deaths per 100 person-years (standardized mortality rate [SMR] 2.84; 95% confidence interval, 2.82 to 2.87). The broadest gaps between observed and expected survival were evident in female (SMR 3.63), black (SMR 3.67), and Hispanic (SMR 4.12) recipients. Standardized mortality ratios declined over time (1990 to 1995, 3.09; 1996 to 2000, 2.90; 2001 to 2007, 2.58). The long-term standardized survival of older recipients was closest to that expected for their age. Heart transplant recipients have considerable long-term survival and have a threefold higher standardized long-term mortality rate than that of the noninstitutionalized population. Long-term mortality rates have consistently declined over time and will likely continue to decrease.

Sections du résumé

BACKGROUND
Heart transplantation is the mainstay of treatment for patients in end-stage heart failure. This study sought to contrast survival after transplantation with that of the general population to quantify standardized mortality rates using a nested case-control study design.
METHODS
Control subjects were noninstitutionalized inhabitants of the United States identified through the National Longitudinal Mortality study. Case subjects were adults who underwent heart transplantation between 1990 and 2007 and identified through the Organ Procurement and Transplantation Network. Propensity-matching (5:1, nearest neighbor, caliper = 0.1) was utilized to identify suitable control subjects based on age, sex, race, and state of permanent residency. The primary study endpoint was 10-year survival.
RESULTS
In all, 31,883 heart transplant recipients were matched to 159,415 noninstitutionalized residents of the United States. The 10-year survival of heart transplant recipients was 53%. The population expected mortality rate was 15.9 deaths per 100 person-years with an observed rate of 45.1 deaths per 100 person-years (standardized mortality rate [SMR] 2.84; 95% confidence interval, 2.82 to 2.87). The broadest gaps between observed and expected survival were evident in female (SMR 3.63), black (SMR 3.67), and Hispanic (SMR 4.12) recipients. Standardized mortality ratios declined over time (1990 to 1995, 3.09; 1996 to 2000, 2.90; 2001 to 2007, 2.58). The long-term standardized survival of older recipients was closest to that expected for their age.
CONCLUSIONS
Heart transplant recipients have considerable long-term survival and have a threefold higher standardized long-term mortality rate than that of the noninstitutionalized population. Long-term mortality rates have consistently declined over time and will likely continue to decrease.

Identifiants

pubmed: 32739258
pii: S0003-4975(20)31220-0
doi: 10.1016/j.athoracsur.2020.05.163
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

889-898

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Alejandro Suarez-Pierre (A)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: alejandro.suarezpierre@cuanschutz.edu.

Cecillia Lui (C)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Xun Zhou (X)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Katherine Giuliano (K)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Eric Etchill (E)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Alejandro Almaraz-Espinoza (A)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Todd C Crawford (TC)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Charles D Fraser (CD)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Glenn J Whitman (GJ)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Chun W Choi (CW)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Robert S Higgins (RS)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Ahmet Kilic (A)

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH